Literature DB >> 16846787

Phagocytosis of apoptotic and necrotic thymocytes is inhibited by PAF-receptor antagonists and affects LPS-induced COX-2 expression in murine macrophages.

Soraya Imon de Oliveira1, Patricia Dias Fernandes, João Gustavo P Amarante Mendes, Sonia Jancar.   

Abstract

There is evidence that apoptotic cells and oxidized low density lipoprotein (oxLDL) particles have common ligands on their surface consisting of oxidized phospholipids which bind to scavenger receptors in macrophages leading to phagocytosis. Some effects of oxLDL binding to its receptor(s) were shown to be inhibited by Platelet Activating Factor (PAF)-receptor antagonists. Thus, we investigated the effect of PAF-receptor antagonists on the phagocytosis of apoptotic, necrotic and viable thymocytes by murine peritoneal macrophages. It was found that phagocytosis of altered cells is significantly increased compared to viable cells, a phenomenon reversed by pre-treatment of macrophages with PAF-receptor antagonists (WEB2170 and CV3988), PAF or oxLDL. Phagocytosis of altered cells induced negligible expression of cyclooxygenase-2 (COX-2) but strongly potentiated the LPS-induced expression of this enzyme. This phenomenon was restricted to altered cells and was reversed by pre-treatment of macrophages with PAF-receptor antagonists. These findings indicate that apoptotic and necrotic cells share common ligands with PAF and oxLDL and suggest the involvement of PAF-like receptors in the enhanced clearance of these cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16846787     DOI: 10.1016/j.prostaglandins.2006.04.002

Source DB:  PubMed          Journal:  Prostaglandins Other Lipid Mediat        ISSN: 1098-8823            Impact factor:   3.072


  11 in total

1.  Platelet-activating factor receptor (PAF-R)-dependent pathways control tumour growth and tumour response to chemotherapy.

Authors:  Soraya I de Oliveira; Luciana N S Andrade; Ana C Onuchic; Sueli Nonogaki; Patrícia D Fernandes; Mônica C Pinheiro; Ciro B S Rohde; Roger Chammas; Sonia Jancar
Journal:  BMC Cancer       Date:  2010-05-13       Impact factor: 4.430

2.  Novel Single Inhibitor of HDAC6/8 and Dual Inhibitor of PI3K/HDAC6 as Potential Alternative Treatments for Prostate Cancer.

Authors:  Fabiana Sélos Guerra; Daniel Alencar Rodrigues; Carlos Alberto Manssour Fraga; Patricia Dias Fernandes
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-21

3.  Topical application of a platelet activating factor receptor agonist suppresses phorbol ester-induced acute and chronic inflammation and has cancer chemopreventive activity in mouse skin.

Authors:  Ravi P Sahu; Samin Rezania; Jesus A Ocana; Sonia C DaSilva-Arnold; Joshua R Bradish; Justin D Richey; Simon J Warren; Badri Rashid; Jeffrey B Travers; Raymond L Konger
Journal:  PLoS One       Date:  2014-11-06       Impact factor: 3.240

4.  Platelet-activating factor (PAF) receptor as a promising target for cancer cell repopulation after radiotherapy.

Authors:  I A da Silva; R Chammas; A P Lepique; S Jancar
Journal:  Oncogenesis       Date:  2017-01-30       Impact factor: 7.485

5.  Apoptotic cells contribute to melanoma progression and this effect is partially mediated by the platelet-activating factor receptor.

Authors:  André Luis Lacerda Bachi; Lívia Caires Dos Santos; Suely Nonogaki; Sônia Jancar; Miriam Galvonas Jasiulionis
Journal:  Mediators Inflamm       Date:  2012-04-22       Impact factor: 4.711

6.  Uptake of oxLDL and IL-10 production by macrophages requires PAFR and CD36 recruitment into the same lipid rafts.

Authors:  Francisco J O Rios; Matheus Ferracini; Mateus Pecenin; Marianna M Koga; Yajuan Wang; Daniel F J Ketelhuth; S Jancar
Journal:  PLoS One       Date:  2013-10-09       Impact factor: 3.240

7.  Clearance of apoptotic cells by macrophages induces regulatory phenotype and involves stimulation of CD36 and platelet-activating factor receptor.

Authors:  Matheus Ferracini; Francisco J O Rios; Mateus Pecenin; Sonia Jancar
Journal:  Mediators Inflamm       Date:  2013-11-20       Impact factor: 4.711

8.  Discovery of Novel Orally Active Tetrahydro-Naphthyl-N-Acylhydrazones with In Vivo Anti-TNF-α Effect and Remarkable Anti-Inflammatory Properties.

Authors:  Natália M Cordeiro; Rosana H C N Freitas; Carlos A M Fraga; Patricia D Fernandes
Journal:  PLoS One       Date:  2016-05-26       Impact factor: 3.240

9.  Platelet-Activating Factor Receptor Ligands Protect Tumor Cells from Radiation-Induced Cell Death.

Authors:  Ildefonso Alves da Silva-Junior; Barbara Dalmaso; Suellen Herbster; Ana Paula Lepique; Sonia Jancar
Journal:  Front Oncol       Date:  2018-02-05       Impact factor: 6.244

Review 10.  New Insights Into the Pathologic Roles of the Platelet-Activating Factor System.

Authors:  Jeffrey B Travers; Joyce G Rohan; Ravi P Sahu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-15       Impact factor: 6.055

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.